Sign inJoin waitlistJoin the waitlist

DM

David Marinier

Associate Program Director · Gundersen Lutheran Medical Foundation

Credentials: · · · · · · ·

History

Gundersen Lutheran Medical Foundation
Present
University of Wisconsin Hospitals and Clinics
Present
University of Wisconsin Hospitals and Clinics
Present

Hematology and Medical Oncology
Loyola University Medical Center
2007–2010
Internal Medicine
Loyola University Medical Center
2004–2007
Loyola University Chicago Stritch School of Medicine
2000–2004

Research

Clinical utility of autopsy after hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation · 2007 · 13 citations
Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
Journal of Geriatric Oncology · 2022 · Last of 6 authors · 7 citations
Primary CNS Leiomyosarcoma in an Immunocompetent Patient
Case report · Journal of Oncology Practice · 2016 · Last of 4 authors · 7 citations

Dipesh Uprety
3 papers · 3 as a fellow
AB
Amir Bista
2 papers · 2 as a fellow
Peter Polewski
2 papers · 1 as a resident
YV
Yazhini Vallatharasu
2 papers · 2 as a fellow
AT
Ahmad Tarhini
1 paper
AR
Ajay Rawal
1 paper
Brendan Curti
1 paper
CB
Charles Bane
1 paper
Cheryl Czerlanis
1 paper · 1 as a fellow
Craig Hofmeister
1 paper
Gary Cohen
1 paper
IN
Ibrahim Nakhoul
1 paper

Clinical trials

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2027–2034
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2026–2030
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027